Opening Remarks

Palliative Care Pathways Across the Lung Cancer Trajectory — From Diagnosis to Survivorship

Symptom Management Beyond Morphine — Updates in Pain and Symptom Science

Palliative Care in the Era of Immunotherapy and Targeted Therapy

AI and telehealth in Indian palliative care setup

Communication, Ethics, and End-of-Life Decision Making. How to tackle, ‘I am fit, but I don’t have any treatment options’

PANEL DISCUSSION: “Bridging the Gaps — Delivering Holistic Palliative Care in Indian Oncology Practice”

CLOSING REMARKS

Design Foundations in Lung Cancer Trials - ICH E8(R1)/E6(R3): Quality by Design and risk-based oversight.

Quiz and Open Q&A

Applied Design Walkthroughs and Pitfalls - Case 1: Metastatic immunotherapy RCT – cross-over mitigation and OS/PFS trade-offs. - Case 2: Peri-operative trial – pCR/MPR endpoints and EFS follow-up. - Avoiding design pitfalls: ambiguous intercurrent event h

Quiz and Open Q&A

Protocol Backbone and Estimand Implementation - Mapping study objectives to estimands.

Inauguration Introduction of Theme

Inside the lung a journey with in

From Discovery to Recovery - A Case Scenario Opening Act

Welcome & Setting an Context

IO Biomarkers in Lung Cancer

Compound mutations on NGS

Significance of TP 53 mutn alone or as a co mutation in Treatment

How to implement multiomic approach in the clinic

PANEL DISCUSSION: Panel discussion: Acceptance of LB NGS reports in Clinic

Significance of TP53 AS A COMPUND mutation in Lung Cancer (02 Slides, 05 Minutes Each)

PANEL DISCUSSION: Role of compound mutations in Lung Adenocarcinoma

ESMO Molecular Classification

Emerging molecular testing paradigms in NSCLC management—current perspectives and recommendations What is new 2025?

CASE BASED DISCUSSION

Rapid fire quiz for DM students